Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 6
2002 6
2003 11
2004 17
2005 20
2006 25
2007 16
2008 26
2009 20
2010 18
2011 22
2012 7
2013 21
2014 13
2015 11
2016 11
2017 15
2018 12
2019 17
2020 18
2021 9
2022 7
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

304 results
Results by year
Filters applied: . Clear all
Page 1
Levocetirizine and montelukast in the COVID-19 treatment paradigm.
May BC, Gallivan KH. May BC, et al. Int Immunopharmacol. 2022 Feb;103:108412. doi: 10.1016/j.intimp.2021.108412. Epub 2021 Dec 15. Int Immunopharmacol. 2022. PMID: 34942461 Free PMC article.
Levocetirizine, a third-generation antihistamine, and montelukast, a leukotriene receptor antagonist, exhibit remarkable synergistic anti-inflammatory activity across a spectrum of signaling proteins, cell adhesion molecules, and leukocytes. ...To investigate patient outco …
Levocetirizine, a third-generation antihistamine, and montelukast, a leukotriene receptor antagonist, exhibit remarkable synergistic …
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Devillier P, Roche N, Faisy C. Devillier P, et al. Clin Pharmacokinet. 2008;47(4):217-30. doi: 10.2165/00003088-200847040-00001. Clin Pharmacokinet. 2008. PMID: 18336052 Review.
When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levocetirizine - many pharmacological and clinical criteria must be considered. ...Of the second-generation antihistamines, desloratadine has th …
When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levoceti …
Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.
Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Mahatme MS, et al. Indian J Pharmacol. 2016 Nov-Dec;48(6):649-653. doi: 10.4103/0253-7613.194854. Indian J Pharmacol. 2016. PMID: 28066101 Free PMC article. Clinical Trial.

Therefore, we aimed to compare the efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine combination in patients of AR. ...The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The

…
Therefore, we aimed to compare the efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadin …
H1-antihistamines for chronic spontaneous urticaria.
Sharma M, Bennett C, Cohen SN, Carter B. Sharma M, et al. Cochrane Database Syst Rev. 2014 Nov 14;2014(11):CD006137. doi: 10.1002/14651858.CD006137.pub2. Cochrane Database Syst Rev. 2014. PMID: 25397904 Free PMC article. Review.
Evidence is limited for desloratadine given at 5 mg once daily in the intermediate term and at 20 mg in the short term. Levocetirizine at 5 mg in the intermediate but not short term was effective for complete suppression. Levocetirizine 20 mg was effective in the sh …
Evidence is limited for desloratadine given at 5 mg once daily in the intermediate term and at 20 mg in the short term. Levocetirizine …
A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Patients With Asthma and Allergic Rhinitis.
Kim MK, Lee SY, Park HS, Yoon HJ, Kim SH, Cho YJ, Yoo KH, Lee SK, Kim HK, Park JW, Park HW, Chung JH, Choi BW, Lee BJ, Chang YS, Jo EJ, Lee SY, Cho YS, Jee YK, Lee JM, Jung J, Park CS. Kim MK, et al. Clin Ther. 2018 Jul;40(7):1096-1107.e1. doi: 10.1016/j.clinthera.2018.04.021. Epub 2018 Jun 24. Clin Ther. 2018. PMID: 29945738 Free article. Clinical Trial.
For all other allergic rhinitis efficacy end points, the montelukast/levocetirizine group showed greater improvement than the montelukast group. ...IMPLICATIONS: The fixed-dose combination of montelukast and levocetirizine was effective and safe in treating perennia …
For all other allergic rhinitis efficacy end points, the montelukast/levocetirizine group showed greater improvement than the montelu …
OTC drugs for seasonal allergies.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Apr 22;61(1570):57-60. Med Lett Drugs Ther. 2019. PMID: 31169808 No abstract available.
Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
Podder I, Das A, Ghosh S, Biswas D, Sengupta S, Chowdhury SN. Podder I, et al. Dermatol Ther. 2020 Nov;33(6):e13946. doi: 10.1111/dth.13946. Epub 2020 Jul 27. Dermatol Ther. 2020. PMID: 32618048 Clinical Trial.
We wanted to compare the effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg in moderate-to-severe CSU. We conducted a double-blind, randomized controlled trial with two groups: bilastine 20 mg (n = 31) and levocetirizine 5 mg (n = 27), …
We wanted to compare the effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg in moderate-to-severe CSU. …
Efficacy of Desloratadine and Levocetirizine in Patients with Cedar Pollen-Induced Allergic Rhinitis: A Randomized, Double-Blind Study.
Yonekura S, Okamoto Y, Sakurai D, Iinuma T, Sakurai T, Yoneda R, Kurita J, Hanazawa T, Kawasaki Y. Yonekura S, et al. Int Arch Allergy Immunol. 2019;180(4):274-283. doi: 10.1159/000503065. Epub 2019 Oct 16. Int Arch Allergy Immunol. 2019. PMID: 31618733 Clinical Trial.
There were 12 subjects in the desloratadine-responsive group and 24 subjects in the levocetirizine-responsive group, with no contributor to response was detected. CONCLUSION: Levocetirizine tended to control nasal symptoms more effectively than desloratadine. ...
There were 12 subjects in the desloratadine-responsive group and 24 subjects in the levocetirizine-responsive group, with no contribu …
Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of the Literature.
Iriarte Sotés P, Armisén M, Usero-Bárcena T, Rodriguez Fernández A, Otero Rivas MM, Gonzalez MT, Meijide Calderón A, Veleiro B; Urtigal, the Galician Group of Interest in Urticaria. Iriarte Sotés P, et al. J Investig Allergol Clin Immunol. 2021 Jul 26;31(4):282-291. doi: 10.18176/jiaci.0649. Epub 2020 Oct 8. J Investig Allergol Clin Immunol. 2021. PMID: 33030434 Free article.
RESULTS: We identified 337 articles, of which 14 were included in the final evaluation (fexofenadine, 6; cetirizine, 2; levocetirizine and desloratadine, 1; levocetirizine, 1; rupatadine, 2; ebastine, 1; and bilastine, 1). ...High fexofenadine doses produced a signi …
RESULTS: We identified 337 articles, of which 14 were included in the final evaluation (fexofenadine, 6; cetirizine, 2; levocetirizine …
304 results